Akari Therapeutics Stock (NASDAQ:AKTX)

Forecast Ownership Financials Chart

Previous Close

$0.77

52W Range

$0.57 - $3.85

50D Avg

$0.98

200D Avg

$1.14

Market Cap

$12.87K

Avg Vol (3M)

$49.72K

Beta

0.27

Div Yield

-

AKTX Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

8

IPO Date

Jan 06, 2014

Website

AKTX Performance

AKTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-21.64M	$-16.81M	$-23.09M
Net Income	$-19.79M	$-10.01M	$-6.97M
EBITDA	$-21.64M	$-16.80M	$-23.08M
Basic EPS	-	-	-
Diluted EPS	-	-	-

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 17Mar 21, 18 | 8:30 AM

Peer Comparison

Ticker	Company
RNTX	Rein Therapeutics Inc.
SLNO	Soleno Therapeutics, Inc.
GYRE	Gyre Therapeutics, Inc.
ACHV	Achieve Life Sciences, Inc.
BNTC	Benitec Biopharma Inc.